Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Hensel

Showing results (21-30 of 59) with videos related to

Pageof 6
Sort By:
Deutsches Arzteblatt International|March 16, 2011
HIV and cancer in GermanyManfred Hensel, Armin Goetzenich, Thomas Lutz, et al.
International Journal of Cancer|April 10, 2007
High rate of centrosome aberrations and correlation with proliferative activity in patients with untreated B-cell chronic lymphocytic leukemiaManfred Hensel, Martin Zoz, Christian Giesecke, et al.
Leukemia Research|November 22, 2005
The bcl-2/IgH rearrangement in a population of 204 healthy individuals: occurrence, age and gender distribution, breakpoints, and detection method validityChristina Schmitt, Brigitta Balogh, Alexander Grundt, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 9, 2019
Response to the letter to the Editor concerning our article "High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany"Stefan Feiten, Geothy Chakupurakal, Hans Peter Feustel, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 13, 2019
High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in GermanyStefan Feiten, Geothy Chakupurakal, Hans Peter Feustel, et al.
Medizinische Klinik (Munich, Germany : 1983)|September 30, 2010
[Assessment of immunoglobulins in a long-term non-interventional study (SIGNS Study). Rationale, design, and methods]Wilhelm Kirch, Ralf Gold, Manfred Hensel, et al.
Journal of Clinical Immunology|September 15, 2012
Treatment of neurological autoimmune diseases with immunoglobulins: first insights from the prospective SIGNS registryMartin Stangel, Ulrich Baumann, Michael Borte, et al.
Stem Cells (Dayton, Ohio)|January 18, 2002
Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell supportManfred Hensel, Andreas Schneeweiss, Hans-Peter Sinn, et al.
Therapeutic Advances in Neurological Disorders|May 3, 2016
Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registryMartin Stangel, Ralf Gold, David Pittrow, et al.
Annals of Hematology|July 31, 2008
Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trialMathias Witzens-Harig, Monika Reiz, Christiane Heiss, et al.
Pageof 6

Showing results (21-30 of 59) with videos related to

Sort By:
Pageof 6
Deutsches Arzteblatt International|March 16, 2011
HIV and cancer in GermanyManfred Hensel, Armin Goetzenich, Thomas Lutz, et al.
International Journal of Cancer|April 10, 2007
High rate of centrosome aberrations and correlation with proliferative activity in patients with untreated B-cell chronic lymphocytic leukemiaManfred Hensel, Martin Zoz, Christian Giesecke, et al.
Leukemia Research|November 22, 2005
The bcl-2/IgH rearrangement in a population of 204 healthy individuals: occurrence, age and gender distribution, breakpoints, and detection method validityChristina Schmitt, Brigitta Balogh, Alexander Grundt, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 9, 2019
Response to the letter to the Editor concerning our article "High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany"Stefan Feiten, Geothy Chakupurakal, Hans Peter Feustel, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 13, 2019
High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in GermanyStefan Feiten, Geothy Chakupurakal, Hans Peter Feustel, et al.
Medizinische Klinik (Munich, Germany : 1983)|September 30, 2010
[Assessment of immunoglobulins in a long-term non-interventional study (SIGNS Study). Rationale, design, and methods]Wilhelm Kirch, Ralf Gold, Manfred Hensel, et al.
Journal of Clinical Immunology|September 15, 2012
Treatment of neurological autoimmune diseases with immunoglobulins: first insights from the prospective SIGNS registryMartin Stangel, Ulrich Baumann, Michael Borte, et al.
Stem Cells (Dayton, Ohio)|January 18, 2002
Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell supportManfred Hensel, Andreas Schneeweiss, Hans-Peter Sinn, et al.
Therapeutic Advances in Neurological Disorders|May 3, 2016
Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registryMartin Stangel, Ralf Gold, David Pittrow, et al.
Annals of Hematology|July 31, 2008
Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trialMathias Witzens-Harig, Monika Reiz, Christiane Heiss, et al.
Pageof 6